Scarica l'app Stockscreener
122.06
10.64%
-14.54
Precedente Chiudi:
$136.60
Aprire:
$135.26
Volume 24 ore:
482.78K
Relative Volume:
1.53
Capitalizzazione di mercato:
$1.74B
Reddito:
$1.30M
Utile/perdita netta:
$-35.78M
Rapporto P/E:
-18.60
EPS:
-6.5624
Flusso di cassa netto:
$-22.82M
1 W Prestazione:
-9.17%
1M Prestazione:
+49.69%
6M Prestazione:
+114.74%
1 anno Prestazione:
+349.08%
Intervallo 1D:
$120.69
$138.83
Intervallo di 1 settimana:
$120.69
$143.76
Portata 52W:
$18.23
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
122.06 | 1.74B | 1.30M | -35.78M | -22.82M | -6.5624 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Mizuho | Outperform |
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella launches disease awareness campaign for rare lymphatic condition - Investing.com Nigeria
Quarterly Earnings: Can Palvella Therapeutics Inc lead its sector in growth2026 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Chipmakers Recap: Can Palvella Therapeutics Inc deliver alphaQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Palvella Therapeutics stock rating maintained at Buy by Clear Street - Investing.com
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations - Yahoo Finance
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN
Published on: 2026-03-07 20:09:49 - baoquankhu1.vn
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Blue Owl Capital Holdings LP Reduces Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment - Stocktwits
Aug Closing: Is Palvella Therapeutics Inc stock trending bullishJuly 2025 Final Week & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Royce & Associates LP Decreases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder - MyChesCo
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares - Investing.com Australia
Palvella Therapeutics raises $230M in upsized stock offering By Investing.com - Investing.com Canada
Palvella Therapeutics raises $230M in upsized stock offering - Investing.com Australia
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares By Investing.com - Investing.com Canada
Palvella therapeutics (PVLA) director buys $500k in stock By Investing.com - Investing.com Australia
Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com South Africa
Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat
Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat
Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing - marketscreener.com
Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Is Palvella Therapeutics (PVLA) Still Attractive After A 7x One-Year Surge In Price? - simplywall.st
PVLA PE Ratio & Valuation, Is PVLA Overvalued - Intellectia AI
Palvella Therapeutics Announces Underwritten Common Stock Offering - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade - Defense World
PVLA Stock Surges 86% With A 6-day Winning Spree On Phase 3 Win - Trefis
Palvella prices $200M stock offering at $125 per share - Investing.com Australia
Strategic Update: PVLA Surges Amid New Growth Plans - timothysykes.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up After Analyst Upgrade - MarketBeat
Palvella Therapeutics shares rise to three-year high on upsized offering - Investing.com UK
Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge - simplywall.st
What is Lifesci Capital's Estimate for PVLA FY2026 Earnings? - MarketBeat
HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings - MarketBeat
Palvella Therapeutics, Inc. (PVLA) Stock Analysis: A Potential 74% Upside in the Biotech Sector - DirectorsTalk Interviews
Palvella Therapeutics announces pricing of upsized public offering - marketscreener.com
Palvella prices $200M stock offering at $125 per share By Investing.com - Investing.com India
Palvella Therapeutics Announces Upsized Public Offering Pricing for February 2026 - geneonline.com
Palvella Therapeutics Announces Pricing of Upsized Public Offering - Bitget
Palvella Therapeutics Announces Pricing Of Upsized Public Offering - TradingView
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho - MarketBeat
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright - Yahoo Finance
BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00 - MarketBeat
Palvella launches $150M public stock offering By Investing.com - Investing.com India
Chardan Capital Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price - Defense World
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):